Droxidopa for the treatment of neurogenic orthostatic hypotension in neurodegenerative diseases

References

• Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Auton Neurosci. 2011;161:46–48.
   PubMed Web of Science ®Google Scholar
• Freeman R. Clinical practice. Neurogenic orthostatic hypotension. N Engl J Med. 2008;358:615–624.
   PubMed Web of Science ®Google Scholar
• Pavy-Le Traon A, Amarenco G, Duerr S, et al. The movement disorders task force review of dysautonomia rating scales in Parkinson’s disease with regard to symptoms of orthostatic hypotension. Mov Disord. 2011;26:1985–1992.
   PubMed Web of Science ®Google Scholar
• Moya A, Sutton R, Ammirati F, et al. Guidelines for the diagnosis and management of syncope (version 2009). Eur Heart J. 2009;30:2631–2671.
   PubMed Web of Science ®Google Scholar
• Allcock LM, Kenny RA, Mosimann UP, et al. Orthostatic hypotension in Parkinson’s disease: association with cognitive decline? Int J Geriatr Psychiatry. 2006;21:778–783.
   PubMed Web of Science ®Google Scholar
• Fedorowski A, Stavenow L, Hedblad B, et al. Orthostatic hypotension predicts all-cause mortality and coronary events in middle-aged individuals (The Malmo Preventive Project). Eur Heart J. 2010;31:85–91.
   PubMed Web of Science ®Google Scholar
• Rose KM, Eigenbrodt ML, Biga RL, et al. Orthostatic hypotension predicts mortality in middle-aged adults: the Atherosclerosis risk in communities (ARIC) study. Circulation. 2006;114:630–636.
   PubMed Web of Science ®Google Scholar
• Azidah AK, Hasniza H, Zunaina E. Prevalence of falls and its associated factors among elderly diabetes in a Tertiary center, Malaysia. Curr Gerontol Geriatr Res. 2012;2012:539073.
   PubMedGoogle Scholar
• Verwoert GC, Mattace-Raso FU, Hofman A, et al. Orthostatic hypotension and risk of cardiovascular disease in elderly people: the Rotterdam study. J Am Geriatr Soc. 2008;56:1816–1820.
   PubMed Web of Science ®Google Scholar
• Low PA. Prevalence of orthostatic hypotension. Clin Auton Res. 2008;18(Suppl 1):8–13.
   PubMed Web of Science ®Google Scholar
• Poon IO, Braun U. High prevalence of orthostatic hypotension and its correlation with potentially causative medications among elderly veterans. J Clin Pharm Ther. 2005;30:173–178.
   PubMed Web of Science ®Google Scholar
• Rutan GH, Hermanson B, Bild DE, et al. Orthostatic hypotension in older adults. The cardiovascular health study. CHS collaborative research group. Hypertension. 1992;19:508–519.
   PubMed Web of Science ®Google Scholar
• Bradley JG, Davis KA. Orthostatic hypotension. Am Fam Physician. 2003;68:2393–2398.
   PubMed Web of Science ®Google Scholar
• Perez-Lloret S, Rey MV, Fabre N, et al. Factors related to orthostatic hypotension in Parkinson’s disease. Parkinsonism Relat Disord. 2012;18:501–505.
   PubMed Web of Science ®Google Scholar
• Pathak A, Lapeyre-Mestre M, Montastruc JL, et al. Heat-related morbidity in patients with orthostatic hypotension and primary autonomic failure. Mov Disord. 2005;20:1213–1219.
   PubMed Web of Science ®Google Scholar
• Narkiewicz K, Cooley RL, Somers VK. Alcohol potentiates orthostatic hypotension: implications for alcohol-related syncope. Circulation. 2000;101:398–402.
   PubMed Web of Science ®Google Scholar
• Velseboer DC, de Haan RJ, Wieling W, et al. Prevalence of orthostatic hypotension in Parkinson’s disease: a systematic review and meta-analysis. Parkinsonism Relat Disord. 2011;17:724–729.
   PubMed Web of Science ®Google Scholar
• Haapaniemi TH, Kallio MA, Korpelainen JT, et al. Levodopa, bromocriptine and selegiline modify cardiovascular responses in Parkinson’s disease. J Neurol. 2000;247:868–874.
   PubMed Web of Science ®Google Scholar
• Kujawa K, Leurgans S, Raman R, et al. Acute orthostatic hypotension when starting dopamine agonists in Parkinson’s disease. Arch Neurol. 2000;57:1461–1463.
   PubMed Web of Science ®Google Scholar
• Mehagnoul-Schipper DJ, Boerman RH, Hoefnagels WH, et al. Effect of levodopa on orthostatic and postprandial hypotension in elderly Parkinsonian patients. J Gerontol A Biol Sci Med Sci. 2001;56:M749–M55.
   PubMed Web of Science ®Google Scholar
• Goldstein DS, Eldadah BA, Holmes C, et al. Neurocirculatory abnormalities in Parkinson disease with orthostatic hypotension: independence from levodopa treatment. Hypertension. 2005;46:1333–1339.
   PubMed Web of Science ®Google Scholar
• Bonuccelli U, Lucetti C, Del DP, et al. Orthostatic hypotension in de novo Parkinson disease. Arch Neurol. 2003;60:1400–1404.
   PubMed Web of Science ®Google Scholar
• Haensch CA, Lerch H, Jorg J, et al. Cardiac denervation occurs independent of orthostatic hypotension and impaired heart rate variability in Parkinson’s disease. Parkinsonism Relat Disord. 2009;15:134–137.
   PubMed Web of Science ®Google Scholar
• Senard JM, Rai S, Lapeyre-Mestre M, et al. Prevalence of orthostatic hypotension in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1997;63:584–589.
   PubMed Web of Science ®Google Scholar
• Donadio V, Incensi A, Del Sorbo F, et al. Skin nerve phosphorylated alpha-synuclein deposits in Parkinson disease with orthostatic hypotension. J Neuropathol Exp Neurol. 2018;77:942–949.
   PubMed Web of Science ®Google Scholar
• Matsui H, Nishinaka K, Oda M, et al. Does cardiac metaiodobenzylguanidine (MIBG) uptake in Parkinson’s disease correlate with major autonomic symptoms? Parkinsonism Relat Disord. 2006;12:284–288.
   PubMed Web of Science ®Google Scholar
• Wenning GK, Colosimo C, Geser F, et al. Multiple system atrophy. Lancet Neurol. 2004;3:93–103.
   PubMed Web of Science ®Google Scholar
• Iodice V, Low DA, Vichayanrat E, et al. Cardiovascular autonomic dysfunction in MSA and Parkinson’s disease: similarities and differences. J Neurol Sci. 2011;310:133–138.
   PubMed Web of Science ®Google Scholar
• Wenning GK, Granata R, Krismer F, et al. Orthostatic hypotension is differentially associated with the cerebellar versus the parkinsonian variant of multiple system atrophy: a comparative study. Cerebellum. 2012;11:223–226.
   PubMed Web of Science ®Google Scholar
• Nagayama H, Ueda M, Yamazaki M, et al. Abnormal cardiac [(123)I]-meta-iodobenzylguanidine uptake in multiple system atrophy. Mov Disord. 2010;25:1744–1747.
   PubMed Web of Science ®Google Scholar
• Garland EM, Hooper WB, Robertson D. Pure autonomic failure. Handb Clin Neurol. 2013;117:243–257.
   PubMedGoogle Scholar
• Low PA, Singer W. Management of neurogenic orthostatic hypotension: an update. Lancet Neurol. 2008;7:451–458.
   PubMed Web of Science ®Google Scholar
• Saito S, Shioda K, Nishijima K. Dopamine dysregulation syndrome including mania related to coadministration of droxidopa. J Clin Psychopharmacol. 2012;32:428–429.
   PubMed Web of Science ®Google Scholar
• FDA approves Northera to treat neurogenic orthostatic hypotension. Washington, DC; 2014 [cited 2018 Sep 16]. Available from: https://www.michaeljfox.org/foundation/news-detail.php?fda-approves-northera-for-orthostatic-hypotension
   Google Scholar
• Seppi K, Chahine LM, Chaudhuri KR, et al. International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord. 2019 Jan 17. doi:10.1002/mds.27602. [Epub ahead of print]
   PubMedGoogle Scholar
• Thompson P, Wright J, Rajkumar C. Non-pharmacological treatments for orthostatic hypotension. Age Ageing. 2011;40:292–293.
   PubMed Web of Science ®Google Scholar
• Logan IC, Witham MD. Efficacy of treatments for orthostatic hypotension: a systematic review. Age Ageing. 2012;41:587–594.
   PubMed Web of Science ®Google Scholar
• Low PA, Gilden JL, Freeman R, et al. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group. JAMA. 1997;277:1046–1051.
   PubMed Web of Science ®Google Scholar
• Mitka M. Trials to address efficacy of midodrine 18 years after it gains FDA approval. JAMA. 2012;307: 1124. 7.
   PubMed Web of Science ®Google Scholar
• Harris G. Backtracks and returns drug to market. The New York Times. FDA. 2010 [cited 2018 Oct 23]. Available from: https://www.nytimes.com/2010/09/04/health/policy/04fda.html
   Google Scholar
• Seppi K, Weintraub D, Coelho M, et al. The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord. 2011;26(Suppl 3):S42–80.
   PubMed Web of Science ®Google Scholar
• Smith W, Wan H, Much D, et al. Clinical benefit of midodrine hydrochloride in symptomatic orthostatic hypotension: a phase 4, double-blind, placebo-controlled, randomized, tilt-table study. Clin Auton Res. 2016;26:269–277.
   PubMed Web of Science ®Google Scholar
• Shibao C, Okamoto L, Biaggioni I. Pharmacotherapy of autonomic failure. Pharmacol Ther. 2012;134:279–286.
   PubMed Web of Science ®Google Scholar
• Shibao C, Okamoto LE, Gamboa A, et al. Comparative efficacy of yohimbine against pyridostigmine for the treatment of orthostatic hypotension in autonomic failure. Hypertension. 2010;56:847–851.
   PubMed Web of Science ®Google Scholar
• Singer W, Sandroni P, Opfer-Gehrking TL, et al. Pyridostigmine treatment trial in neurogenic orthostatic hypotension. Arch Neurol. 2006;63:513–518.
   PubMed Web of Science ®Google Scholar
• Senard JM, Rascol O, Rascol A, et al. Lack of yohimbine effect on ambulatory blood pressure recording: a double-blind cross-over trial in parkinsonians with orthostatic hypotension. Fundam Clin Pharmacol. 1993;7:465–470.
   PubMed Web of Science ®Google Scholar
• Kaufmann H. L-Dihydroxyphenylserine (Droxidopa): a new therapy for neurogenic orthostatic hypotension: the US experience. Clin Auton Res. 2008;18(Suppl 1):19–24.
   PubMed Web of Science ®Google Scholar
• Bartholini J, Constantinidis J, Puig M, et al. The stereoisomers of 3,4-dihydroxyphenylserine as precursors of norepinephrine. J Pharmacol Exp Ther. 1975;193:523–532.
   PubMed Web of Science ®Google Scholar
• Goldstein DS. L-Dihydroxyphenylserine (L-DOPS): a norepinephrine prodrug. Cardiovasc Drug Rev. 2006;24:189–203.
   PubMed Web of Science ®Google Scholar
• Maruyama W, Naoi M, Narabayashi H. The metabolism of L-DOPA and L-threo-3,4-dihydroxyphenylserine and their effects on monoamines in the human brain: analysis of the intraventricular fluid from parkinsonian patients. J Neurol Sci. 1996;139:141–148.
   PubMed Web of Science ®Google Scholar
• Chen JJ, Hewitt LA. Comparison of the pharmacokinetics of droxidopa after dosing in the fed versus fasted state and with 3-times-daily dosing in healthy elderly subjects. Drugs R D. 2018;18:77–86.
   PubMed Web of Science ®Google Scholar
• Goldstein DS, Holmes C, Kaufmann H, et al. Clinical pharmacokinetics of the norepinephrine precursor L-threo-DOPS in primary chronic autonomic failure. Clin Auton Res. 2004;14:363–368.
   PubMed Web of Science ®Google Scholar
• Tohgi H, Abe T, Takahashi S, et al. Effect of a synthetic norepinephrine precursor, L-threo-3,4- dihydroxyphenylserine on the total norepinephrine concentration in the cerebrospinal fluid of parkinsonian patients. Neurosci Lett. 1990;116:194–197.
   PubMed Web of Science ®Google Scholar
• Holmes C, Whittaker N, Heredia-Moya J, et al. Contamination of the norepinephrine prodrug droxidopa by dihydroxyphenylacetaldehyde. Clin Chem. 2010;56:832–838.
   PubMed Web of Science ®Google Scholar
• Kurihara J, Takata Y, Suzuki S, et al. Effect of midodrine on chlorpromazine-induced orthostatic hypotension in rabbits: comparison with amezinium, etilefrine and droxidopa. Biol Pharm Bull. 2000;23:1445–1449.
   PubMed Web of Science ®Google Scholar
• Iwase S, Mano T, Kunimoto M, et al. Effect of L-threo-3,4-dihydroxyphenylserine on muscle sympathetic nerve activity in humans. J Auton Nerv Syst. 1992;39:159–167.
   PubMedGoogle Scholar
• Palma JA, Norcliffe-Kaufmann L, Martinez J, et al. Supine plasma NE predicts the pressor response to droxidopa in neurogenic orthostatic hypotension. Neurology. 2018;91:e1539–e44.
   PubMed Web of Science ®Google Scholar
• Lamotte G, Holmes C, Sullivan P, et al. Substantial renal conversion of L-threo-3,4-dihydroxyphenylserine (droxidopa) to norepinephrine in patients with neurogenic orthostatic hypotension. Clin Auton Res. 2018.
   PubMed Web of Science ®Google Scholar
• Freeman R, Young J, Landsberg L, et al. The treatment of postprandial hypotension in autonomic failure with 3,4-DL-threo-dihydroxyphenylserine. Neurology. 1996;47:1414–1420.
   PubMed Web of Science ®Google Scholar
• Freeman R, Landsberg L, Young J. The treatment of neurogenic orthostatic hypotension with 3,4-DL-threo-dihydroxyphenylserine: a randomized, placebo-controlled, crossover trial. Neurology. 1999;53:2151–2157.
   PubMed Web of Science ®Google Scholar
• Mathias CJ, Senard JM, Braune S, et al. L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure. Clin Auton Res. 2001;11:235–242.
   PubMed Web of Science ®Google Scholar
• Kaufmann H, Saadia D, Voustianiouk A, et al. Norepinephrine precursor therapy in neurogenic orthostatic hypotension. Circulation. 2003;108:724–728.
   PubMed Web of Science ®Google Scholar
• Mathias CJ. L-dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension: the European experience. Clin Auton Res. 2008;18(Suppl 1):25–29.
   PubMed Web of Science ®Google Scholar
• Kaufmann H, Freeman R, Biaggioni I, et al. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial. Neurology. 2014;83:328–335.
   PubMed Web of Science ®Google Scholar
• Biaggioni I, Freeman R, Mathias CJ, et al. Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa. Hypertension. 2015;65:101–107.
   Google Scholar
• Hauser RA, Hewitt LA, Isaacson S. Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson’s disease (NOH306A). J Parkinsons Dis. 2014;4:57–65.
   PubMedGoogle Scholar
• Hauser RA, Isaacson S, Lisk JP, et al. Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson’s disease (nOH306B). Mov Disord. 2015;30:646–654.
   PubMed Web of Science ®Google Scholar
• Hauser RA, Heritier S, Rowse GJ, et al. Droxidopa and reduced falls in a trial of Parkinson disease patients with neurogenic orthostatic hypotension. Clin Neuropharmacol. 2016;39:220–226.
   PubMed Web of Science ®Google Scholar
• Elgebaly A, Abdelazeim B, Mattar O, et al. Meta-analysis of the safety and efficacy of droxidopa for neurogenic orthostatic hypotension. Clin Auton Res. 2016;26:171–180.
   Google Scholar
• Isaacson S, Shill HA, Vernino S, et al. Safety and durability of effect with long-term, open-label droxidopa treatment in patients with symptomatic neurogenic orthostatic hypotension (NOH303). J Parkinsons Dis. 2016;6:751–759.
   PubMedGoogle Scholar
• Francois C, Hauser RA, Aballea S, et al. Cost-effectiveness of droxidopa in patients with neurogenic orthostatic hypotension: post-hoc economic analysis of Phase 3 clinical trial data. J Med Econ. 2016;19:515–525.
   PubMed Web of Science ®Google Scholar
• Fedorowski A, Melander O. Syndromes of orthostatic intolerance: a hidden danger. J Intern Med. 2013;273:322–335.
   PubMed Web of Science ®Google Scholar
• McDonald C, Newton JL, Burn DJ. Orthostatic hypotension and cognitive impairment in Parkinson’s disease: causation or association? Mov Disord. 2016;31:937–946.
   PubMed Web of Science ®Google Scholar
• Francois C, Rowse GJ, Hewitt LA, et al. Analysis of number needed to treat for droxidopa in patients with symptomatic neurogenic orthostatic hypotension. Clin Auton Res. 2016;16:143.
   Google Scholar
• White WB, Hewitt LA, Mehdirad AA. Impact of the norepinephrine prodrug droxidopa on the QTc interval in healthy individuals. Clin Pharmacol Drug Dev. 2018;7:332–340.
   PubMed Web of Science ®Google Scholar
• White WB, Hauser RA, Rowse GJ, et al. Cardiovascular safety of droxidopa in patients with symptomatic neurogenic orthostatic hypotension. Am J Cardiol. 2017;119:1111–1115.
   PubMed Web of Science ®Google Scholar
• Goldstein DS, Holmes C, Sewell L, et al. Effects of carbidopa and entacapone on the metabolic fate of the norepinephrine prodrug L-DOPS. J Clin Pharmacol. 2011;51:66–74.
   PubMed Web of Science ®Google Scholar
• Biaggioni I, Arthur Hewitt L, Rowse GJ, et al. Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension. BMC Neurol. 2017;17:90.
   PubMed Web of Science ®Google Scholar
• Espay AJ, LeWitt PA, Hauser RA, et al. Neurogenic orthostatic hypotension and supine hypertension in Parkinson’s disease and related synucleinopathies: prioritisation of treatment targets. Lancet Neurol. 2016;15:954–966.
   PubMed Web of Science ®Google Scholar
• Northera Prescribing Information. Chelsea Therapeutics. 2014 [cited 2018 Sep 14]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/203202lbl.pdf
   Google Scholar
• Chen JJ, Han Y, Tang J, et al. Standing and supine blood pressure outcomes associated with droxidopa and midodrine in patients with neurogenic orthostatic hypotension: a Bayesian meta-analysis and mixed treatment comparison of randomized trials. Ann Pharmacother. 2018. DOI:1060028018786954.
   Web of Science ®Google Scholar
• Iida N, Koshikawa S, Akizawa T, et al. Effects of L-threo-3,4-dihydroxyphenylserine on orthostatic hypotension in hemodialysis patients. Am J Nephrol. 2002;22:338–346.
   PubMed Web of Science ®Google Scholar
• Biaggioni I, Robertson RM. Hypertension in orthostatic hypotension and autonomic dysfunction. Cardiol Clin. 2002;20:291–301,vii.
   PubMedGoogle Scholar
• Kaufmann H, Norcliffe-Kaufmann L, Hewitt LA, et al. Effects of the novel norepinephrine prodrug, droxidopa, on ambulatory blood pressure in patients with neurogenic orthostatic hypotension. J Am Soc Hypertens. 2016;10:819–826.
   PubMed Web of Science ®Google Scholar
• Jamnadas-Khoda J, Koshy S, Mathias CJ, et al. Are current recommendations to diagnose orthostatic hypotension in Parkinson’s disease satisfactory? Mov Disord. 2009;24:1747–1751.
   PubMed Web of Science ®Google Scholar
• Perez-Lloret S, Rey MV, Pavy-Le Traon A, et al. Emerging drugs for autonomic dysfunction in Parkinson’s disease. Expert Opin Emerg Drugs. 2013;18:39–53.
   PubMed Web of Science ®Google Scholar
• Hauser RA, Hewitt LA, Isaacson S. Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson’s disease (NOH306A). J Parkinsons Dis. 2014;4:57–65.
   PubMedGoogle Scholar
• Fukada K, Endo T, Yokoe M, et al. L-threo-3,4-dihydroxyphenylserine (L-DOPS) co-administered with entacapone improves freezing of gait in Parkinson’s disease. Med Hypotheses. 2013;80:209–212.
   PubMed Web of Science ®Google Scholar
• Fornai F, Di Poggio AB, Pellegrini A, et al. Noradrenaline in Parkinson’s disease: from disease progression to current therapeutics. Curr Med Chem. 2007;14:2330–2334.
   PubMed Web of Science ®Google Scholar
• Fujisaki K, Kanai H, Hirakata H, et al. Midodrine hydrochloride and L-threo-3,4-dihydroxy-phenylserine preserve cerebral blood flow in hemodialysis patients with orthostatic hypotension. Ther Apher Dial. 2007;11:49–55.
   PubMed Web of Science ®Google Scholar